Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

NCT02124746 is registered in ClinicalTrials.gov with Sierra Oncology LLC - a GSK company as lead sponsor.

NCT NCT02124746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02124746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Lead sponsor
Sierra Oncology LLC - a GSK company
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2014
Completion date
December 6, 2018
Enrollment
87 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythemia, polycythemia vera, post-essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis, primary myelofibrosis